TSZY(SZ:002872) Jing Ji Guan Cha Wang·2026-02-12 03:14Group 1 - The core viewpoint of the articles highlights that ST Tian Sheng (002872) is facing additional risk warnings due to historical fund misappropriation by its controlling shareholder and penalties from the China Securities Regulatory Commission [1] - The company and its subsidiaries have three products that are likely to be selected for the national drug procurement program, which could expand their sales scope and increase market share if contracts are finalized [1] Group 2 - In the past week, ST Tian Sheng's stock price has increased by 7.82%, with a single-day increase of 2.14% on February 11, closing at 5.24 yuan [2] - Technical indicators show that the stock price has broken through the 20-day moving average, and the MACD indicator has turned positive, indicating a stronger short-term performance compared to the pharmaceutical sector [2]